518 related articles for article (PubMed ID: 30324488)
21. Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?
Méjean A; Ravaud A; Thezenas S; Chevreau C; Bensalah K; Geoffrois L; Thiery-Vuillemin A; Cormier L; Lang H; Guy L; Gravis G; Rolland F; Linassier C; Lechevallier E; Oudard S; Laguerre B; Gross-Goupil M; Bernhard JC; Colas S; Albiges L; Lebret T; Treluyer JM; Timsit MO; Escudier B
Eur Urol; 2021 Oct; 80(4):417-424. PubMed ID: 34187771
[TBL] [Abstract][Full Text] [Related]
22. The Association Between Cytoreductive Nephrectomy and Overall Survival in Metastatic Renal Cell Carcinoma with Primary Tumor Size ≤4 cm.
Tappero S; Barletta F; Piccinelli ML; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Tian Z; Parodi S; Dell'Oglio P; Palumbo C; Briganti A; De Cobelli O; Chun FKH; Graefen M; Longo N; Ahyai S; Saad F; Shariat SF; Suardi N; Borghesi M; Terrone C; Karakiewicz PI
Eur Urol Focus; 2023 Sep; 9(5):742-750. PubMed ID: 36906483
[TBL] [Abstract][Full Text] [Related]
23. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.
Bhindi B; Graham J; Wells JC; Bakouny Z; Donskov F; Fraccon A; Pasini F; Lee JL; Basappa NS; Hansen A; Kollmannsberger CK; Kanesvaran R; Yuasa T; Ernst DS; Srinivas S; Rini BI; Bowman I; Pal SK; Choueiri TK; Heng DYC
Eur Urol; 2020 Oct; 78(4):615-623. PubMed ID: 32362493
[TBL] [Abstract][Full Text] [Related]
24. Cytoreductive nephrectomy: does CARMENA (Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques) change everything?
Grant M; Szabados B; Kuusk T; Powles T; Bex A
Curr Opin Urol; 2020 Jan; 30(1):36-40. PubMed ID: 31789991
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy.
Fukuda H; Takagi T; Kondo T; Yoshida K; Shimizu S; Nagashima Y; Tanabe K
Int J Clin Oncol; 2018 Jun; 23(3):539-546. PubMed ID: 29302841
[TBL] [Abstract][Full Text] [Related]
26. Metastatic renal cell carcinoma patients of T4 stage who are in status of N1 stage or older than 76 years cannot benefit from cytoreductive nephrectomy.
Zhang Z; Wu H; Yang T; Wu Y; Yu N; Xu Z
BMC Cancer; 2020 Sep; 20(1):844. PubMed ID: 32883242
[TBL] [Abstract][Full Text] [Related]
27. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy.
Hahn AW; Kotecha RR; Viscuse PV; Pieretti AC; Wiele AJ; Jonasch E; Lee CH; Gao J; Zurita AJ; Shah AY; Campbell MT; Sharma P; Motzer RJ; Russo P; Wood CG; Tannir NM; Voss MH; Karam JA; Hakimi AA; Msaouel P
Eur Urol Focus; 2023 Sep; 9(5):734-741. PubMed ID: 36863962
[TBL] [Abstract][Full Text] [Related]
28. Cytoreductive nephrectomy for metastatic renal cell carcinoma.
Chery LJ; Karam JA; Wood CG
Clin Adv Hematol Oncol; 2016 Sep; 14(9):696-703. PubMed ID: 27673288
[TBL] [Abstract][Full Text] [Related]
29. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.
Bakouny Z; El Zarif T; Dudani S; Connor Wells J; Gan CL; Donskov F; Shapiro J; Davis ID; Parnis F; Ravi P; Steinharter JA; Agarwal N; Alva A; Wood L; Kapoor A; Ruiz Morales JM; Kollmannsberger C; Beuselinck B; Xie W; Heng DYC; Choueiri TK
Eur Urol; 2023 Feb; 83(2):145-151. PubMed ID: 36272943
[TBL] [Abstract][Full Text] [Related]
30. Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study.
Marchioni M; Bandini M; Preisser F; Tian Z; Kapoor A; Cindolo L; Primiceri G; Berardinelli F; Briganti A; Shariat SF; Schips L; Karakiewicz PI
Eur Urol Focus; 2019 May; 5(3):488-496. PubMed ID: 29229582
[TBL] [Abstract][Full Text] [Related]
31. Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a bibliographic review.
Faba OR; Brookman-May SD; Linares E; Breda A; Pisano F; Subiela JD; Sanguedolce F; Brausi M; Palou J
World J Urol; 2017 Dec; 35(12):1807-1816. PubMed ID: 28702843
[TBL] [Abstract][Full Text] [Related]
32. Reassessing the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in 2019.
Psutka SP; Chang SL; Cahn D; Uzzo RG; McGregor BA
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():276-283. PubMed ID: 31099657
[TBL] [Abstract][Full Text] [Related]
33. Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting.
Ljungberg B; Sundqvist P; Lindblad P; Kjellman A; Thorstenson A; Hellström M; Kröger Dahlin BI; Thomasson M; Harmenberg U; Lundstam S
Scand J Urol; 2020 Dec; 54(6):487-492. PubMed ID: 32897123
[TBL] [Abstract][Full Text] [Related]
34. Role of cytoreductive nephrectomy in the targeted therapy era: A systematic review and meta-analysis.
García-Perdomo HA; Zapata-Copete JA; Castillo-Cobaleda DF
Investig Clin Urol; 2018 Jan; 59(1):2-9. PubMed ID: 29333508
[TBL] [Abstract][Full Text] [Related]
35. Renal cell carcinoma and brain metastasis: Questioning the dogma of role for cytoreductive nephrectomy.
Daugherty M; Daugherty E; Jacob J; Shapiro O; Mollapour M; Bratslavsky G
Urol Oncol; 2019 Mar; 37(3):182.e9-182.e15. PubMed ID: 30528396
[TBL] [Abstract][Full Text] [Related]
36. [Symptomatic renal tumours in metastatic renal cell carcinoma - surgical options].
Gilbert N; Merseburger AS; Kramer M
Aktuelle Urol; 2018 Sep; 49(5):417-421. PubMed ID: 30184600
[TBL] [Abstract][Full Text] [Related]
37. Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?
Larcher A; Wallis CJD; Bex A; Blute ML; Ficarra V; Mejean A; Karam JA; Van Poppel H; Pal SK
Eur Urol Oncol; 2019 Jul; 2(4):365-378. PubMed ID: 31109902
[TBL] [Abstract][Full Text] [Related]
38. External validation of the REMARCC model for the selection of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma: A multicenter retrospective study.
Okita K; Hatakeyama S; Naito S; Numakura K; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Nishiyama H; Ito A; Kojima Y; Habuchi T; Obara W; Tsuchiya N; Ohyama C
Urol Oncol; 2021 Dec; 39(12):836.e11-836.e17. PubMed ID: 34544649
[TBL] [Abstract][Full Text] [Related]
39. The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Real-World Multi-Institutional Analysis.
Ghatalia P; Handorf EA; Geynisman DM; Deng M; Zibelman MR; Abbosh P; Anari F; Greenberg RE; Viterbo R; Chen D; Smaldone MC; Kutikov A; Uzzo RG
J Urol; 2022 Jul; 208(1):71-79. PubMed ID: 35212574
[TBL] [Abstract][Full Text] [Related]
40. Deferred cytoreductive nephrectomy in the management of metastatic renal cell carcinoma: A systematic review and meta-analysis.
Britton CJ; Andrews JR; Wallis CJD; Sharma V; Leibovich BC; Thompson RH; Boorjian SA; Bhindi B; Costello BA
Urol Oncol; 2023 Mar; 41(3):125-136. PubMed ID: 38832909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
